Katharina E. Meijboom

Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy

Suzan M. Hammond, Gareth Hazell, Fazel Shabanpoor et al. · Proceedings of the National Academy of Sciences · 2016 · 193 citations · Full text

Pharmacy, Neuroscience, Pharmacology +16

Reducing Ventral Tegmental Dopamine D2 Receptor Expression Selectively Boosts Incentive Motivation

Johannes W. de Jong, Theresia J. M. Roelofs, Frédérique Mol et al. · Neuropsychopharmacology · 2015 · 74 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

CRISPR/Cas9-mediated excision of ALS/FTD-causing hexanucleotide repeat expansion in C9ORF72 rescues major disease mechanisms in vivo and in vitro

Katharina E. Meijboom, Abbas Abdallah, Nicholas P. Fordham et al. · Nature Communications · 2022 · 70 citations · Full text

Life Sciences, Genetics, Neuroscience +17

Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice

Lisa Walter, Marc‐Olivier Deguise, Katharina E. Meijboom et al. · EBioMedicine · 2018 · 47 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Combining multiomics and drug perturbation profiles to identify muscle-specific treatments for spinal muscular atrophy

Katharina E. Meijboom, Viola Volpato, Jimena Monzón‐Sandoval et al. · JCI Insight · 2021 · 20 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17